Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trialof the Gruppo Italiano per lo Studio dei Linfomi (GISL)-Reference-Cited by-同舟云学术

Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trialof the Gruppo Italiano per lo Studio dei Linfomi (GISL)

Published:2010-09-17 Issue:3 Volume:90 Page:323-330
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Ferrario Andrea, ,Merli Francesco,Luminari Stefano,Stelitano Caterina,Mannina Donato,Russo Mario,Mazza Patrizio,Marcheselli Luigi,Goldaniga Maria Cecilia,Federico Massimo,Baldini Luca

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-010-1067-1.pdf

Reference35 articles.

1. Jaffe ES, Harris NL, Stein H, Vardiman JW (2001) World Health Organization classification of tumours of hematopoietic and lymphoid tissues, 3rd edn. IARC, Lyon

2. Ben-Ezra J, Burke JS, Swartz WG, Brownell MD, Brynes RK, Hill LR et al (1989) Small lymphocytic lymphoma: a clinicopathologic analysis of 268 cases. Blood 73:579–587

3. Coiffier B, Thieblemont C, Felman P, Salles G, Berger F (1999) Indolent non follicular lymphomas: characteristics, treatment, and outcome. Semin Hematol 36:198–208

4. Landgren O, Tilly H (2008) Epidemiology, pathology and treatment of non-follicular indolent lymphomas. Leuk Lymphoma 49(Suppl 1):35–42

5. Pangalis GA, Angelopoulou MK, Vassilakopoulos TP, Siakantaris MP, Kittas C (1999) B-chronic lymphocytic leukemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenstrom’s macroglobulinemia: a clinical, morphologic, and biologic spectrum of similar disorders. Semin Hematol 36:104–114

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing therapy for nodal marginal zone lymphoma;Blood;2016-04-28

2. A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma;Leukemia & Lymphoma;2016-02-08

3. Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non-Hodgkin lymphomas: A retrospective cohort study;Leukemia Research;2015-12

4. Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation Guidelines for the Management of Indolent, Nonfollicular B-Cell Lymphoma (Marginal Zone, Lymphoplasmacytic, and Small Lymphocytic Lymphoma);Clinical Lymphoma Myeloma and Leukemia;2015-02

5. Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas;Leukemia & Lymphoma;2014-01-24